Humana’s (HUM) “Neutral” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Humana (NYSE:HUM) in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a $360.00 target price on the insurance provider’s stock.

Several other analysts also recently issued reports on the company. Piper Sandler initiated coverage on Humana in a research note on Wednesday, June 26th. They set an overweight rating and a $392.00 price target for the company. Wells Fargo & Company decreased their price target on Humana from $413.00 to $350.00 and set an overweight rating for the company in a research note on Monday, April 8th. Baird R W upgraded Humana to a hold rating in a research note on Thursday, May 30th. Barclays cut their price objective on Humana from $356.00 to $310.00 and set an equal weight rating for the company in a research report on Tuesday, April 2nd. Finally, UBS Group cut their price objective on Humana from $334.00 to $326.00 and set a neutral rating for the company in a research report on Thursday, April 25th. Fourteen research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of Hold and an average target price of $402.60.

Humana Stock Performance

HUM opened at $392.63 on Tuesday. The company has a market cap of $47.31 billion, a PE ratio of 24.45, a price-to-earnings-growth ratio of 2.23 and a beta of 0.51. The stock has a 50-day moving average of $365.66 and a 200-day moving average of $347.24. Humana has a 52-week low of $298.61 and a 52-week high of $530.54. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.67 and a current ratio of 1.67.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.12 by $1.11. The company had revenue of $29.61 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The firm’s revenue was up 10.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $9.38 EPS. As a group, equities research analysts forecast that Humana will post 16.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humana

Several large investors have recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Humana in the 4th quarter valued at approximately $676,800,000. Sanders Capital LLC acquired a new position in shares of Humana in the 4th quarter worth approximately $489,300,000. Ontario Teachers Pension Plan Board raised its holdings in shares of Humana by 11,647.2% in the 1st quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock worth $367,342,000 after buying an additional 1,050,459 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Humana by 0.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 984,618 shares of the insurance provider’s stock worth $450,749,000 after buying an additional 8,164 shares in the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Humana by 47.4% in the 1st quarter. Janus Henderson Group PLC now owns 975,097 shares of the insurance provider’s stock worth $338,026,000 after buying an additional 313,530 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.